Dr. Kathryn Henrie Melamed, MD

Dr. Melamed practices at Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health.

Dr. Melamed's NPI, 1700148335, was assigned on June 11, 2012. Dr. Melamed graduated from David Geffen School of Medicine at UCLA in 2012. Dr. Melamed holds California license A134639.

Dr. Melamed's primary practice is Ronald Reagan UCLA Medical Center, at 757 Westwood Plaza, Los Angeles, CA 90095 in Los Angeles County. The practice phone is (310) 825-6301.

Dr. Melamed's primary practice is Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health. Dr. Melamed is also affiliated with UCLA Santa Monica Medical Center. The medical group on file is Harbor-UCLA Medical Center. Dmand AI also links Dr. Melamed to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Melamed practices, 4 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Melamed's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Melamed is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Melamed's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists acute respiratory failure, asthma, chronic lung disease, chronic obstructive pulmonary disease (COPD), pneumonia, pulmonary fibrosis and tobacco use among the conditions Dr. Melamed treats.

CMS data shows 449 Medicare services from Dr. Melamed across 10 procedure codes in 2024, for 197 Medicare patients. Medicare paid $42,276 for them.

CMS counts 197 Medicare patients who saw Dr. Melamed in 2024. The largest group is 75 to 84, with 77 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 35% are also on Medicaid. Their average risk score is 3.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Melamed's median patient age at 65, with 52% women.

In 2024, Dr. Melamed wrote 569 Medicare Part D claims for 102 patients. 50% of them were for generic drugs. CMS names the drug for 470 of them, across 18 drugs with 11 or more claims each, at $125,519 in total drug cost. In 2023, CMS named 278 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Melamed for performance year 2024, reported as part of a group. Dr. Melamed accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Melamed as offering telehealth.

Dmand AI links 4 papers to Dr. Melamed, published from 2011 to 2017. Dr. Melamed has published most often in Circulation. Dr. Melamed's most frequent co-authors are Fereidoun G. Abtin, MD, James Richard Berenson, MD and Donald St. Paul Gravenor, MD.

CMS Open Payments shows 34 general payments to Dr. Melamed from 17 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $319.

Dr. Melamed graduated from David Geffen School of Medicine at UCLA in 2012.

Dr. Melamed is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.